XOMA Corporation (XOMA)
| Market Cap | 238.75M |
| Revenue (ttm) | 40.49M |
| Net Income (ttm) | 9.79M |
| Shares Out | 11.45M |
| EPS (ttm) | 0.85 |
| PE Ratio | 24.53 |
| Forward PE | 30.49 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,654 |
| Open | 20.97 |
| Previous Close | 21.24 |
| Day's Range | 20.53 - 21.26 |
| 52-Week Range | 15.68 - 32.09 |
| Beta | 0.93 |
| Analysts | Buy |
| Price Target | 63.75 (+205.76%) |
| Earnings Date | Mar 14, 2023 |
About XOMA
XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 a... [Read more]
Financial Performance
In 2021, XOMA's revenue was $38.16 million, an increase of 29.86% compared to the previous year's $29.39 million. Earnings were $7.79 million, a decrease of -11.44%.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for XOMA stock is "Buy." The 12-month stock price forecast is $63.75, which is an increase of 205.76% from the latest price.
News
XOMA Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
EMERYVILLE, Calif., Jan. 06, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”), the Biotech Royalty Aggregator, today announced the Company has granted Owen Hughes, th...
New Executive Leadership Team Appointed to Accelerate XOMA's Differentiated Royalty Monetization Strategy
Owen Hughes appointed Executive Chairman of the Board of Directors and Brad Sitko joins as Chief Investment Officer
XOMA Declares Quarterly Preferred Stock Dividends
EMERYVILLE, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to ho...
XOMA Acquires Royalty and Milestone License to Ebopiprant, a Preterm Labor Asset, Being Developed by Organon
XOMA assumes the rights to ebopiprant from ObsEva, including the Organon License, Patent Estate, and Merck KGaA, Darmstadt, Germany, license, for a $15 million outlay
Xoma (XOMA) Reports Q3 Loss, Misses Revenue Estimates
Xoma (XOMA) delivered earnings and revenue surprises of -140% and 95.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
XOMA Reports Third Quarter 2022 Financial Results and Highlights Recent Operational Events
Received first recurring royalty-style payment from Roche related to faricimab, its newly launched therapy for wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). First five...
XOMA to Present at H.C. Wainwright 24th Annual Global Investment Conference
EMERYVILLE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of improvi...
Xoma (XOMA) Reports Q2 Loss, Misses Revenue Estimates
Xoma (XOMA) delivered earnings and revenue surprises of -381.82% and 88.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
XOMA Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Events
The completion of Regeneron's acquisition of Checkmate Pharmaceuticals resulted in a $5 million milestone payment to Kuros, $2.5 million of which was paid to XOMA in July.
Kuros Biosciences: Completion of the Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Triggers a $5 Million Milestone Payment
Ad-hoc announcement pursuant to Article 53 of the SIX listing rules
XOMA to Present at H.C. Wainwright Global Investment Conference
EMERYVILLE, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of improving...
Xoma (XOMA) Reports Q1 Loss, Misses Revenue Estimates
Xoma (XOMA) delivered earnings and revenue surprises of 5.88% and 12.73%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
XOMA Reports First Quarter 2022 Financial Results and Highlights Recent Operational Events
Earned a $2 million milestone from Rezolute as it dosed the final patient in a Phase 2 open-label study of RZ358 in patients with congenital hyperinsulinism in early 2022. Rezolute has announced its ...
XOMA to Present at Oppenheimer's 32nd Annual Healthcare Conference
EMERYVILLE, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of improvi...
XOMA Reports Full Year 2021 Financial Results and Highlights Recent Operational Events
Earned $35 million milestone payment as NIS793 entered Phase 3 clinical study in metastatic pancreatic cancer
XOMA to Present at the 42nd Annual Cowen Health Care Conference
EMERYVILLE, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of improvi...
XOMA to Present at Aegis Capital Corp Investor Conference
EMERYVILLE, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of improvin...
XOMA to Present at Upcoming Investor Conferences
EMERYVILLE, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of improvin...
XOMA Announces Evolution of Company Leadership and Succession Planning
Chief Executive Officer Jim Neal appointed as Chairman; Former Chairman W. Denman Van Ness to remain Lead Independent Director
XOMA Earns $35 Million Milestone Payment as Anti-TGFβ Antibody Enters Phase 3 Clinical Study in Metastatic Pancreatic Cancer
EMERYVILLE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) announced today NIS793, an anti-TGFβ monoclonal antibody licensed from the Company, has advanced to the Phase 3 de...
XOMA Reports Third Quarter 2021 Financial Results and Highlights Recent Operational Events
Added eight assets to its portfolio of potential milestone and royalty assets in 2021
Will Xoma (XOMA) Report Negative Q3 Earnings? What You Should Know
Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in Xoma (XOMA): Can Its 11.2% Jump Turn into More Strength?
Xoma (XOMA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
XOMA to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
EMERYVILLE, Calif., Sept. 22, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA)'s Chief Executive Officer, Jim Neal, will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Confere...
XOMA to Present at H.C. Wainwright 23rd Annual Global Investment Conference
EMERYVILLE, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present at the H.C. Wainwright 23rd Annual Global Inv...